No information is available on the use of repaglinide during breastfeeding. Repaglinide is a weak acid that is over 98% protein bound, so it is unlikely to pass into breastmilk in clinically important amounts. Monitor breastfed infants for signs of hypoglycemia such as jitteriness, excessive sleepiness, poor feeding, seizures cyanosis, apnea, or hypothermia. If there is concern, monitoring of the breastfed infant's blood glucose is advisable during maternal therapy with repaglinide.[1] However, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.
关于哺乳期使用瑞格列奈的信息尚无可用资料。瑞格列奈是一种弱酸，其蛋白结合率超过98%，因此不太可能以具有临床意义的量进入母乳。监测母乳喂养婴儿是否有低血糖迹象，如烦躁不安、过度嗜睡、喂养不佳、惊厥、发绀、呼吸暂停或体温过低。如有疑虑，在母亲接受瑞格列奈治疗期间，建议监测母乳喂养婴儿的血糖。[1] 然而，可能更倾向于使用替代药物，尤其是在哺育新生儿或早产儿期间。
